SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,943,000 | +120.8% | 63,084 | +49.5% | 0.01% | +33.3% |
| Q3 2020 | $880,000 | -70.1% | 42,185 | -65.9% | 0.01% | -68.4% |
| Q2 2020 | $2,939,000 | +528.0% | 123,732 | +376.6% | 0.02% | +375.0% |
| Q1 2020 | $468,000 | -65.0% | 25,963 | -54.0% | 0.00% | -33.3% |
| Q4 2019 | $1,339,000 | -90.6% | 56,440 | -89.1% | 0.01% | -92.6% |
| Q3 2019 | $14,197,000 | -14.5% | 516,643 | +3.0% | 0.08% | -21.4% |
| Q2 2019 | $16,605,000 | +4.7% | 501,783 | +10.9% | 0.10% | +83.9% |
| Q1 2019 | $15,858,000 | +188.6% | 452,586 | +173.6% | 0.06% | +5.7% |
| Q4 2018 | $5,495,000 | +51.8% | 165,413 | +109.2% | 0.05% | +194.4% |
| Q1 2018 | $3,621,000 | +177.5% | 79,058 | +141.5% | 0.02% | +157.1% |
| Q4 2017 | $1,305,000 | +178.8% | 32,740 | +116.8% | 0.01% | +75.0% |
| Q1 2017 | $468,000 | – | 15,101 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |